Literature DB >> 28958894

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.

David F Stroncek1, Bronwen E Shaw2, Brent R Logan3, Deidre M Kiefer4, Bipin N Savani5, Paolo Anderlini6, Christopher N Bredeson7, Peiman Hematti8, Siddhartha Ganguly9, Miguel Angel Diaz10, Hisham Abdel-Azim11, Ibrahim Ahmed12, Dipnarine Maharaj13, Matthew Seftel14, Amer Beitinjaneh15, Sachiko Seo16, Jean A Yared17, Joerg Halter18, Paul V O'Donnell19, Gregory A Hale20, Zachariah DeFilipp19, Hillard Lazarus21, Jane L Liesveld22, Zheng Zhou23, Pashna Munshi24, Richard F Olsson25, Kimberly Anne Kasow26, Jeffrey Szer27, Galen E Switzer28, Pintip Chitphakdithai4, Nirali Shah29, Dennis L Confer4, Michael A Pulsipher11.   

Abstract

Little is known about the experiences of individuals donating peripheral blood stem cells (PBSCs) or marrow for a second time. To study this, unrelated donors making a second donation through the National Marrow Donor Program between 2004 and 2013 were evaluated. Experiences of second-time donors giving marrow (n = 118: first donation was PBSC in 76 and marrow in 42) were compared with those making only 1 marrow donation (n = 5829). Experiences of second-time donors giving PBSCs (n = 602) (first donation was PBSCs in 362; marrow in 240) were compared to first-time PBSC donors (n = 16,095). For donors giving a second PBSC or marrow donation there were no significant differences in maximum skeletal pain, maximum symptoms measured by an established modified toxicity criteria, and recovery time compared with those who donated only once. Notably, the yield of marrow nucleated cells and PBSC CD34+ cells with second donations was less. As previously noted with single first-time donations, female (PBSCs and marrow) and obese donors (PBSCs) had higher skeletal pain and/or toxicity with a second donation. PBSC donors who experienced high levels of pain or toxicity with the first donation also experienced high levels of these symptoms with their second donation and slower recovery times. In conclusion, for most donors second donation experiences were similar to first donation experiences, but CD34+ yields were less. Knowledge of the donor's first experience and stem cell yields may help centers decide whether second donations are appropriate and institute measures to improve donor experiences.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone marrow; Hematopoietic cell transplantation; Peripheral blood stem cells; Unrelated donor

Mesh:

Substances:

Year:  2017        PMID: 28958894      PMCID: PMC5743544          DOI: 10.1016/j.bbmt.2017.09.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  21 in total

1.  Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency.

Authors:  A Tichelli; J Passweg; T Hoffmann; M Gregor; T Kühne; G Favre; A Wodnar-Filipowicz; A Gratwohl
Journal:  Br J Haematol       Date:  1999-07       Impact factor: 6.998

2.  Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience.

Authors:  P Anderlini; M Donato; K W Chan; Y O Huh; A P Gee; M J Lauppe; R E Champlin; M Körbling
Journal:  Transfusion       Date:  1999-06       Impact factor: 3.157

3.  Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait.

Authors:  Sandhya R Panch; Yu Ying Yau; Courtney D Fitzhugh; Matthew M Hsieh; John F Tisdale; Susan F Leitman
Journal:  Transfusion       Date:  2016-05       Impact factor: 3.157

4.  Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections.

Authors:  P Anderlini; J Lauppe; D Przepiorka; D Seong; R Champlin; M Körbling
Journal:  Br J Haematol       Date:  1997-02       Impact factor: 6.998

5.  Second donation of granulocyte-colony-stimulating factor-mobilized peripheral blood progenitor cells: risk factors associated with a low yield of CD34+ cells.

Authors:  Uwe Platzbecker; Martin Bornhäuser; Kristin Zimmer; Linda Lerche; Claudia Rutt; Gerhard Ehninger; Kristina Hölig
Journal:  Transfusion       Date:  2005-01       Impact factor: 3.157

6.  Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors.

Authors:  R Ordemann; K Hölig; K Wagner; U Rautenberg; M Bornhäuser; F Kroschinsky; J Schäfer; U Schuler; G Ehninger
Journal:  Bone Marrow Transplant       Date:  1998-06       Impact factor: 5.483

7.  Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.

Authors:  Jack W Hsu; John R Wingard; Brent R Logan; Pintip Chitphakdithai; Gorgun Akpek; Paolo Anderlini; Andrew S Artz; Chris Bredeson; Steven Goldstein; Gregory Hale; Peiman Hematti; Sarita Joshi; Rammurti T Kamble; Hillard M Lazarus; Paul V O'Donnell; Michael A Pulsipher; Bipin N Savani; Raquel M Schears; Bronwen E Shaw; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-12       Impact factor: 5.742

8.  Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Bronwen E Shaw; John R Wingard; Hillard M Lazarus; Edmund K Waller; Matthew Seftel; David F Stroncek; Angela M Lopez; Dipnarine Maharaj; Peiman Hematti; Paul V O'Donnell; Alison W Loren; Susan F Leitman; Paolo Anderlini; Steven C Goldstein; John E Levine; Willis H Navarro; John P Miller; Dennis L Confer
Journal:  Blood       Date:  2012-10-29       Impact factor: 22.113

Review 9.  Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program.

Authors:  Charles D Bolan; Robert J Hartzman; Elizabeth H Perry; Lance Trainor; John Miller; Rebecca Miller; Lori Hanley; Pintip Chitphakdithai; Roberta J King
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

10.  Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; John P Miller; Brent R Logan; Roberta J King; J Douglas Rizzo; Susan F Leitman; Paolo Anderlini; Michael D Haagenson; Seira Kurian; John P Klein; Mary M Horowitz; Dennis L Confer
Journal:  Blood       Date:  2009-02-03       Impact factor: 22.113

View more
  2 in total

1.  Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations.

Authors:  Sandhya R Panch; Brent Logan; Jennifer A Sees; Stephanie Bo-Subait; Bipin Savani; Nirali N Shah; Jack W Hsu; Galen Switzer; Hillard M Lazarus; Paolo Anderlini; Peiman Hematti; Dennis Confer; Michael A Pulsipher; Bronwen E Shaw; David F Stroncek
Journal:  Transplant Cell Ther       Date:  2021-03-09

2.  Donor-intrinsic variables determine mobilization efficiency: analyses from a cohort of sixty twice-mobilized stem cell donors.

Authors:  Soo-Zin Kim-Wanner; Seo-Youn Lee; Erhard Seifried; Halvard Bonig
Journal:  J Transl Med       Date:  2020-12-18       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.